Poster Listing
P001
AAV next generation vectors
Mathieu Mevel
Nantes Université, CHU de Nantes, TaRGeT - Translational Research in Gene Therapy, INSERM UMR 1089, F-44200 Nantes, France
Chemically-engineered recombinant Adeno-Associated Virus: how chemistry improve rAAV liver gene delivery
P002
AAV next generation vectors
Kathleen Börner
Asklepios BioPharmaceutical (AskBio), Heidelberg, Germany
Characterisation of AAVs in NHPs and rodents using the AskBio Capsid screening (ABCs) platform
P003
AAV next generation vectors
John Mitchell
Montreal Children’s Hospital, Montreal, Quebec
Sustained efficacy and safety up to 3.5 years in adults with glycogen storage disease type Ia (GSDIa): longer-term results from a phase 1/2 clinical trial of DTX401, an AAV8-mediated, liver-directed gene therapy
P004
AAV next generation vectors
Verena Mehlfeld
ViGeneron GmbH
A novel dual AAV approach for intravitreal gene therapy of Stargardt disease
P005
AAV next generation vectors
David Anderson
SwanBio Therapeutics, Inc., PA 19004, USA
Selection of clinical doses for SBT101, an AAV9-hABCD1 vector for the treatment of adrenomyeloneuropathy
P006
AAV next generation vectors
Jessica Wiseman
University of Sheffield
Gene Replacement Therapy for Spastic Paraplegia 47
P007
AAV next generation vectors
David Anderson
SwanBio Therapeutics, Inc., PA 19004, USA
Optimization of intrathecal delivery of an infused AAV9 vector for delivery of a gene therapy candidate for adrenomyeloneuropathy in non-human primates
P008
AAV next generation vectors
James Zengel
Department of Microbiology and Immunology, Stanford University School of Medicine
Hardwiring tissue-specific AAV transduction in mice through engineered receptor expression
P009
AAV next generation vectors
Christian Schön
Boehringer-Ingelheim Pharma GmbH & Co. KG
Characterization of engineered AAV capsids in the retina of mice and in two novel human retina ex vivo models
P010
AAV next generation vectors
Hiroyuki Nakai
Oregon Health & Science University
Barcode screening identifies AAV-KP1 as an AAV capsid that efficiently transduces pancreatic islets with minimal off-target consequences following retrograde pancreatic duct injection in non-human primates
P011
AAV next generation vectors
Jennifer Green
Solid Biosciences
Further characterization of a novel AAV vector and expanded selection criteria platform for muscle gene delivery
P012
AAV next generation vectors
Luned Badder
Division of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, Wales
Delivery of suicide therapies using a precision virotherapy; novel approaches for pancreatic cancer